RPRX up +56.90% percent right now. $RPRX High is at 10.25

New Post Public Reply Private Reply Replies (0) Message Board
Lucky Jimmy
RPRX up +56.90% percent right now. $RPRX High is at 10.25 and the Low 7.66 with current volume of 8,183,000.

Recent News posted below.

RPRX Repros Therapeutics Inc Recent Headline News

Nasdaq stocks posting largest percentage increases
AP - Fri Nov 07, 5:08PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
SWIR: 33.90 (+0.30), PERI: 5.75 (-0.35), UNXL: 5.31 (+0.77), TREE: 47.03 (+3.12), SSRI: 5.20 (+0.88), STMP: 42.92 (+0.93), RPRX: 10.12 (+3.67), NYNY: 7.74 (-0.22), SHLD: 42.81 (+10.14), AREX: 10.73 (+1.88), PGNX: 5.37 (+0.76), ECYT: 6.03 (-0.46), SSO.TO: 5.90 (+0.95), SGMA: 7.21 (-0.64), SW.TO: 38.39 (-0.04), PLNR: 6.40 (+0.01)

Sears Soars Nearly +40% As REIT News Boosts Confidence
at The Street - Fri Nov 07, 2:42PM CST
Repros Therapeutics Inc (NASDAQ:RPRX), Sears Holdings Corp (NASDAQ:SHLD) and Allied Nevada Gold Corp. (NYSEMKT:ANV) are among the top-gaining billionaire stock picks of the day. On the losing end ar...
ANV: 1.05 (+0.19), AMSC: 1.17 (-0.19), RPRX: 10.12 (+3.67), SHLD: 42.81 (+10.14), STAY: 18.30 (-5.00)

Repros Therapeutics (RPRX) Stock Skyrockets After Meeting with FDA About Androxal
at The Street - Fri Nov 07, 10:07AM CST
Shares of Repros Therapeutics (RPRX) soared in morning trading Friday after the biopharmaceutical company held what it called a "constructive meeting" with the FDA regarding its testosterone-boosting drug Androxal.
RPRX: 10.12 (+3.67)

Repros Holds Constructive Meeting With FDA Regarding Androxal(R) NDA Filing
GlobeNewswire - Thu Nov 06, 3:21PM CST
-- No New Clinical Studies Requested
RPRX: 10.12 (+3.67)

Will Repros (RPRX) Miss Estimates This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 2:12PM CST
Repros Therapeutics Inc. (RPRX) has an earnings ESP of 0.00% and a Zacks Rank #4 (Sell).
MNK: 91.06 (-3.49), PBH: 32.79 (-4.53), RPRX: 10.12 (+3.67), HSP: 56.32 (-0.32)

63.7% Return Seen to Date on SmarTrend Repros Therapeutics Call (RPRX)
Comtex SmarTrend(R) - Mon Nov 03, 10:56AM CST
SmarTrend identified a Downtrend for Repros Therapeutics (NASDAQ:RPRX) on September 4th, 2014 at $17.86. In approximately 2 months, Repros Therapeutics has returned 63.72% as of today's recent price of $6.48.
RPRX: 10.12 (+3.67)

Technical Coverage of Pharma Stocks - Repros Therapeutics, Nektar Therapeutics, Akorn, AcelRx Pharma, and Pernix Therapeutics Holdings
PR Newswire - Mon Nov 03, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Repros Therapeutics Inc. (NASDAQ: RPRX), Nektar Therapeutics (NASDAQ: NKTR), Akorn Inc. (NASDAQ: AKRX), AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX), and Pernix Therapeutics Holdings Inc. (NASDAQ: PTX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, October 31, 2014, the NASDAQ Composite ended at 4,630.74, up 1.41%, the Dow Jones Industrial Average advanced 1.13%, to finish the day at 17,390.52, and the S&P 500 closed at 2,018.05, up 1.17%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 778.85, up 0.51%, with the index also advancing 10.60% in the previous three months. Register for your complimentary reports on these five stocks at:
ACRX: 6.04 (+0.41), PTX: 9.09 (-0.17), AKRX: 36.59 (-1.29), RPRX: 10.12 (+3.67), NKTR: 13.35 (-0.21)

Repros to Webcast Investor and Analyst Day on October 31st
GlobeNewswire - Mon Oct 27, 3:01PM CDT
Repros Therapeutics Inc.(Nasdaq:RPRX) today announced that it will host a live webcast of its Investor and Analyst Day that is being held in New York City on Friday, October 31, 2014 beginning at 7:30 a.m. Eastern Time.
RPRX: 10.12 (+3.67)

Biotech Stock Roundup: AbbVie Calls off Shire Acquisition, Will Amgen Consider Breakup? - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Oct 22, 10:18AM CDT
Will Amgen (AMGN) go the Abbott (ABT) way and split into two separate companies?
PCYC: 133.49 (-3.63), NPSP: 27.49 (+0.15), RPRX: 10.12 (+3.67), AMGN: 160.25 (-0.10), ABBV: 61.50 (-1.21), REGN: 377.84 (+0.90), CELG: 106.45 (-0.69)

SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Violations of Federal Securities Laws by the Board of Directors of Repros Therapeutics Inc. - RPRX
PR Newswire - Mon Oct 20, 12:33PM CDT
Levi & Korsinsky, LLP is investigating Repros Therapeutics Inc. ("Repros" or the "Company" (NasdaqCM: RPRX) in connection with possible violations of federal securities laws.
RPRX: 10.12 (+3.67)

INVESTOR ALERT: Investigation of Repros Therapeutics Inc. Announced by Glancy Binkow & Goldberg LLP
Business Wire - Mon Oct 20, 9:36AM CDT
Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of Repros Therapeutics Inc. ("Repros Therapeutics" or the "Company" (NASDAQ: RPRX) concerning possible violations of federal securities laws. The investigation focuses on certain statements issued by the Company concerning the Company's business and financial prospects.
RPRX: 10.12 (+3.67)

Repros Therapeutics Down 64.6% Since SmarTrend Downtrend Call (RPRX)
Comtex SmarTrend(R) - Mon Oct 20, 9:08AM CDT
SmarTrend identified a Downtrend for Repros Therapeutics (NASDAQ:RPRX) on September 4th, 2014 at $17.86. In approximately 2 months, Repros Therapeutics has returned 64.61% as of today's recent price of $6.32.
RPRX: 10.12 (+3.67)

Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Repros Therapeutics Inc.
PR Newswire - Mon Oct 20, 8:00AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Repros Therapeutics, Inc. ("Repros Therapeutics" or the "Company" (NasdaqCM: RPRX -News). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484.
RPRX: 10.12 (+3.67)

INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Repros Therapeutics Inc. (RPRX) To Contact The Firm
PR Newswire - Fri Oct 17, 7:28PM CDT
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Repros Therapeutics Inc. ("Repros" or the "Company" (NASDAQ: RPRX).
RPRX: 10.12 (+3.67)

GE and Urban Outfitters are big market movers
AP - Fri Oct 17, 3:31PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
URBN: 31.18 (+0.02), GE: 26.41 (+0.05), CLV: 10.77 (+0.44), RPRX: 10.12 (+3.67), CLF: 11.17 (+0.63), ATHN: 123.82 (-1.94), MS: 35.66 (+0.35)

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Repros Therapeutics Inc. - RPRX
Business Wire - Fri Oct 17, 2:17PM CDT
The Rosen Law Firm announces that it is investigating potential securities claims against Repros Therapeutics Inc. (NASDAQ: RPRX) resulting from allegations that the Company may have issued materially misleading business information to the investing public.
RPRX: 10.12 (+3.67)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Anthropic Bears Get New Tools, But Daily Risk Bites

Updated Category News Views 8

A $81.3 Billion Offering Invites Fast Money Anthropic arrived in public markets with the sort of numbers that make traders reach for both a calculator and a helmet. The company priced 980 million Class A shares at $83 on November 18, 2026, raising roughly $81.3 billion, then opened at $111.50 when it began Nasdaq trading on November 19. That is a monster debut by any...

Continue Reading
DKSH's Vietnam Oncology Pact Carries Real Promise, Risk

Updated Category News Views 5

A cancer-market announcement ought to make investors pause before they reach for a spreadsheet. Specialised Therapeutics and DKSH have signed an exclusive partnership to bring oncology therapies into Vietnam, and the human case is painfully clear: the country recorded an estimated 180,000 new cancer cases and more than 120,000 deaths annually in the 2022 GLOBOCAN data....

Continue Reading
Build-A-Bear Lawsuit Notice Carries a Date Problem

Updated Category News Views 39

Something is badly out of sequence in the Build-A-Bear shareholder alert, and that matters before anybody gets carried away by the legal boilerplate. The notice says investors who bought NYSE: BBW securities from March 28, 2026 through August 26, 2026 may be covered by a proposed federal securities class action. It also says the lead-plaintiff deadline is January 19,...

Continue Reading
Australia Leads TTW's 2027 Global Travel Country List

Updated Category News Views 43

A travel ranking is a map, not a balance sheet, and that distinction matters more than the glossy numbering. TTW has put Australia at the head of its editorial list of the 50 best countries to visit in 2027, followed by Switzerland, Japan, Canada and Thailand. Fair enough. Those are formidable tourism brands with the scenery, infrastructure and cultural pull to back up...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 445

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading

Top 5 Most Recently Viewed Articles

Amicus Therapeutics Plans Third Quarter 2025 Earnings Call

Updated Category News Views 159

Amicus Therapeutics to Discuss Q3 2025 Financial Results Amicus Therapeutics (NASDAQ: FOLD) is preparing for an important financial discussion as it will host a conference call on November 4, 2025, at 8:30 a.m. ET. This call aims to provide insights into the company’s financial performance for the quarter ending September 30, 2025. Conference Call Participation...

Continue Reading
Cineplex Inc. Hits New Milestones In Q2 2025 Financials

Updated Category News Views 223

Cineplex Reports Impressive Growth in Second Quarter Financials Cineplex Inc. (TSX: CGX) has announced its financial performance for the second quarter of 2025, revealing remarkable growth across various metrics. The company’s total revenues surged to CAD 361.8 million, representing a robust 30.5% increase compared to the same period last year. This performance can be...

Continue Reading
Pinnacle Mergers & Acquisitions Finalizes $151M Deal with Dream Motor Group

Updated Category News Views 545

Pinnacle Mergers & Acquisitions Completes a Major Sale DALLAS — Pinnacle Mergers & Acquisitions, a premier automotive buy-sell advisory firm, has finalized the significant sale of Toyota of Montgomery and Lexus of Montgomery to the renowned Dream Motor Group, led by famed coach Nick Saban and automotive expert Joe Agresti. The deal is valued at an impressive $151...

Continue Reading
Atria Development Corporation Appoints New Vice President

Updated Category News Views 80

Atria Development Corporation Welcomes New Leadership Atria Development Corporation is thrilled to announce that Durval Terceira has been appointed as the new Vice President of Business Development and Labour Relations. With his impressive background, he brings a wealth of experience that is expected to steer the company towards its future goals. Durval Terceira: An...

Continue Reading
Ark Invest's Strategic Shift: Selling Block Inc. Shares

Updated Category News Views 289

Ark Invest Adjusts Its Strategy Cathie Wood's Ark Invest has recently made headlines by selling off a portion of its holdings in Block Inc. This decision, valued at an impressive $4.8 million, signifies a potential shift in investment strategy ahead of Block's forthcoming earnings report. Investors are closely monitoring this move as it coincides with Block's rising...

Continue Reading